TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17599306

Group type: EXPERIMENTAL
Intervention: Oral metronidazole (250 mg 4 times per day) for 10 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg 4 times per day) for 10 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Oral metronidazole (250 mg 4 times per day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg 4 times per day)
Number of subjects: 172
Study: 16301160

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate Restorative Material
Number of subjects: 0
Study: 12088304

Group type: EXPERIMENTAL
Intervention: Threshold electrical stimulation (TES)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (inactive stimulators)
Number of subjects: 57
Study: 9696952

Group type: EXPERIMENTAL
Intervention: Felodipine IV
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nifedipine IV
Number of subjects: 122
Study: 7730907

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg/kg/dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 104
Study: 2913806

Group type: EXPERIMENTAL
Intervention: 0.5 ml of 0.01% intracameral carbachol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.25 ml of 0.01% intracameral carbachol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.1 ml of 0.01% intracameral carbachol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Balanced salt solution (0.1 or 0.5 ml) - Control group
Number of subjects: 32
Study: 31950604

Group type: EXPERIMENTAL
Intervention: Spironolactone (up to 50 mg/day)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 527
Study: 31307856

Group type: EXPERIMENTAL
Intervention: NASA Mission X (MX) program, 8-week intervention
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 245
Study: 28283797

Group type: COMPARATOR
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protandim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 26304977

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study: 23382081

Group type: EXPERIMENTAL
Intervention: Gufoni liberatory maneuver (GLM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 72
Study: 21681118

Group type: COMPARATOR
Intervention: Standard-dose gefitinib (250 mg daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Low-dose gefitinib (dose reduced due to toxicities)
Number of subjects: 114
Study: 18549692

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg daily for 9 days starting on day 2 of menses
Number of subjects: 318

Group type: COMPARATOR
Intervention: Gonadotrophin 75 IU intramuscularly daily for 5 days starting on day 3 of menses
Number of subjects: 318
Study: 16571154

Group type: EXPERIMENTAL
Intervention: High-phenol extra-virgin olive oil (high-EVOO; 592 mg total phenols/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-phenol extra-virgin olive oil (low-EVOO; 147 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-phenol extra-virgin olive oil (high-EVOO)
Number of subjects: 10
Study: 14506534

Group type: EXPERIMENTAL
Intervention: Prone position (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supine position (n = 21)
Number of subjects: 42
Study: 10858346

Group type: EXPERIMENTAL
Intervention: Imiquimod (IQ) treatment
Number of subjects: 0
Study: 9200356

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rhSOD intratracheally
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhSOD intratracheally
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: rhSOD treatment groups
Number of subjects: 33
Study: 8433420

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus best medical care (n = 91)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Best medical care alone (n = 98)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (for patients with crescendo TIAs)
Number of subjects: 189
Study: 3319013

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 23

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 23
Study: 31886592

Group type: EXPERIMENTAL
Intervention: Subcrestal implants (1-3 mm)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Equicrestal implants
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 11
Study: 29733995

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local Ischemic Preconditioning (LIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 26934211

Group type: EXPERIMENTAL
Intervention: Rehabilitation with destabilization devices
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rehabilitation without destabilization devices (control group)
Number of subjects: 26
Study: 26361756

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises (SE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham rESWT combined with supervised exercises (SE)
Number of subjects: 144
Study: 23057435

Group type: EXPERIMENTAL
Intervention: Tetracaine 1%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry (USP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SP‐3000P
Number of subjects: 50
Study: 21769961

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19139363

Group type: EXPERIMENTAL
Intervention: CEE+MPA (Conjugated Equine Estrogen with Medroxyprogesterone Acetate)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: CEE-Alone (Conjugated Equine Estrogen Alone)
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1403
Study: 16356358

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle-modification intervention (40-hour educational course over 4 weeks)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study: 15277161

Group type: COMPARATOR
Intervention: Reduced-fat salad dressing (6 g canola oil)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Full-fat salad dressing (28 g canola oil)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fat-free salad dressing (0 g canola oil)
Number of subjects: 7
Study: 10932511

Group type: EXPERIMENTAL
Intervention: Norgestrel 0.5 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyproterone acetate 1 mg/day
Number of subjects: 64
Study: 9059197

Group type: EXPERIMENTAL
Intervention: Extradural morphine 0.06 mg kg‐1 at the end of surgery and a second dose 6 h later
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with i.v. morphine 0.2 mg kg‐1 after surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received PCA with morphine 0.04 mg kg‐1 i.v.
Number of subjects: 40
Study: 8346593

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional antihypertensive treatment
Number of subjects: 70
Study: 3732360

Group type: EXPERIMENTAL
Intervention: 200 mg mexiletine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 400 mg mexiletine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg disopyramide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg disopyramide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29078739

Group type: EXPERIMENTAL
Intervention: Combination of berberine, arbutin, and birch (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of berberine, arbutin, birch, and forskolin (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proanthocyanidins (group C)
Number of subjects: 0
Study: 27513312

Group type: EXPERIMENTAL
Intervention: MDRD equation
Number of subjects: 9308

Group type: COMPARATOR
Intervention: CKD-EPI equation
Number of subjects: 9308
Study: 24787968

Group type: EXPERIMENTAL
Intervention: Docetaxel after disease progression with abiraterone acetate
Number of subjects: 23
Study: 22283620

Group type: EXPERIMENTAL
Intervention: Active LED phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo LED phototherapy
Number of subjects: 0
Study: 20920126

Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breathing spontaneously (Control)
Number of subjects: 20
Study: 18367689

Group type: EXPERIMENTAL
Intervention: Responsivity education (RE)/prelinguistic milieu teaching (PMT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 51
Study: 16116958

Group type: EXPERIMENTAL
Intervention: PMA (phorbol 12‐myristate 13‐acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMA and AP‐1 cis‐element decoy oligodeoxynucleotides (decoy ODNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMA and AP‐1 mutant decoy ODNs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 0
Study: 12576305

Group type: EXPERIMENTAL
Intervention: Ginger pretreatment (1,000 and 2,000 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin infusion (0.1 and 0.2 U/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13
Study: 10380244

Group type: COMPARATOR
Intervention: Trained Teacher condition
Number of subjects: 759

Group type: COMPARATOR
Intervention: Specialist condition
Number of subjects: 759

Group type: COMPARATOR
Intervention: Health-related physical education program
Number of subjects: 759
Study: 9051704

Group type: EXPERIMENTAL
Intervention: Pravastatin at standard therapeutic doses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Simvastatin at standard therapeutic doses
Number of subjects: 7
Study: 8229380

Group type: EXPERIMENTAL
Intervention: Sliding screwplate
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ender nailing
Number of subjects: 113

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 113
Study: 3885103

Group type: EXPERIMENTAL
Intervention: Chlamydiazyme enzyme immunoassay
Number of subjects: 514

Group type: COMPARATOR
Intervention: Isolation of Chlamydia trachomatis in cycloheximide‐treated McCoy cells
Number of subjects: 514
Study: 30219067

Group type: EXPERIMENTAL
Intervention: Telephone calls or text messages intervention
Number of subjects: 1155
Study: 25616874

Group type: EXPERIMENTAL
Intervention: 4 hours of leg compression after radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 72 hours of leg compression after radiofrequency ablation
Number of subjects: 0
Study: 24240575

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily of cholecalciferol combined with 100 mg of elemental calcium administered twice a day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (100 mg daily of elemental calcium administered twice a day)
Number of subjects: 158
Study: 22687235

Group type: COMPARATOR
Intervention: Usual care (care provided by the GP at the patient's own initiative)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regular monitoring by a practice nurse
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All care modes (self-management, regular monitoring, usual care)
Number of subjects: 180
Study: 18955545

Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Office-based intervention
Number of subjects: 83
Study: 18302711

Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) with bortezomib
Number of subjects: 303

Group type: COMPARATOR
Intervention: Total Therapy 2 (TT2)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) in FGFR3 subgroup
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) matched with 300 patients by standard prognostic factors
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) for patients completing TT2 consolidation within 24 months
Number of subjects: 303
Study: 16019881

Group type: EXPERIMENTAL
Intervention: Alternative computer input devices (14 keyboards and pointing devices)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adjusting existing workstation and customizing computer settings
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined approach of using alternative devices and customizing settings
Number of subjects: 35
Study: 12462290

Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg once daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10478810

Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amrinone (1 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no drug administered)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milrinone and Amrinone
Number of subjects: 30
Study: 9156883

Group type: EXPERIMENTAL
Intervention: Broncho-fibroscopy and bronchoalveolar lavage (BAL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monitoring parameters: heart rate (HR), arterial blood pressure (ABP) and arterial O2 saturation (SaO2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation during the investigation
Number of subjects: 60
Study: 1878318

Group type: EXPERIMENTAL
Intervention: Acoustic startle probes (white noise bursts [50 ms; 95 dBA]) during extinction of aversively conditioned visual stimulus.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conditioned startle reflex augmentation.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Judged aversiveness to slides.
Number of subjects: 60
Study: 6393868

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 197

Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 197
Study: 31976023

Group type: EXPERIMENTAL
Intervention: Proximal Gastrectomy (PG)
Number of subjects: 2217

Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 2217
Study: 28714376

Group type: EXPERIMENTAL
Intervention: Rivaroxaban or Apixaban
Number of subjects: 127

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 127
Study: 26494411

Group type: COMPARATOR
Intervention: Once daily thoracic radiotherapy (TRT) of 42 Gy in 15 fractions (OD)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Twice daily thoracic radiotherapy (TRT) of 45 Gy in 30 fractions (BID)
Number of subjects: 157
Study: 24907435

Group type: EXPERIMENTAL
Intervention: MP0112 (0.04 to 3.6 mg, single intravitreal injection)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MP0112 (0.04-0.4 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MP0112 (1.0 or 2.0 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MP0112 (higher-dose cohorts)
Number of subjects: 32
Study: 22294470

Group type: EXPERIMENTAL
Intervention: Midostaurin (75 mg twice daily for 2 days; 75 mg once on day 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moxifloxacin (active control)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study: 20817247

Group type: EXPERIMENTAL
Intervention: 0.5 mL 24% sucrose solution
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0.5 mL sterile water
Number of subjects: 59
Study: 17588420

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 479

Group type: COMPARATOR
Intervention: Noncoated sutures
Number of subjects: 479
Study: 16240960

Group type: EXPERIMENTAL
Intervention: Direct application of Clearfil AP‐X
Number of subjects: 20

Group type: COMPARATOR
Intervention: Directly applied Filtek Z 250
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indirectly applied Clearfil AP‐X
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indirectly applied Filtek Z 250
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulpal dentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remote dentin
Number of subjects: 20
Study: 12000209

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 75 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9527740

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoflurane (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Induced hypotension (all groups)
Number of subjects: 24
Study: 7638640

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mitomycin 12 mg/m2 given as an intravenous infusion every 6 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Crossover to paclitaxel therapy after progression on mitomycin
Number of subjects: 81
Study: 2199599

Group type: EXPERIMENTAL
Intervention: Single-dose 500-mg clotrimazole vaginal tablets
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Candida isolated at follow-up visit
Number of subjects: 55
Study: 773082

Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31870139

Group type: EXPERIMENTAL
Intervention: Biosimilar monoclonal antibodies awareness
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Perception of cost saving
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Concerns about immunogenicity
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Interchangeability perception
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Confidence in using biosimilars
Number of subjects: 151
Study: 28813414

Group type: EXPERIMENTAL
Intervention: Oral synbiotic preparation (Lactobacillus plantarum plus fructooligosaccharide)
Number of subjects: 4556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4556
Study: 25370591

Group type: EXPERIMENTAL
Intervention: FIFA 11+ warm-up programme
Number of subjects: 265

Group type: COMPARATOR
Intervention: Regular training routine
Number of subjects: 265
Study: 23510607

Group type: EXPERIMENTAL
Intervention: Mailed letter
Number of subjects: 4115

Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 4115

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4115
Study: 21527122

Group type: EXPERIMENTAL
Intervention: Vilazodone (40 mg/d)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 19056600

Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 11 mg total ARs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 22 mg total ARs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 44 mg total ARs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study: 17462119

Group type: EXPERIMENTAL
Intervention: Tramadol users
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 15657470

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal (GI value of 77)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal (GI value of 37)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both HGI and LGI meals
Number of subjects: 8
Study: 11527284

Group type: EXPERIMENTAL
Intervention: Extended treatment protocol including individual certified nursing assistants (CNAs), in-service training for CNAs, and memory notebooks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 0
Study: 9815587

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporine A (12.5 mg/kg/day for 5 days) with continuous-infusion vinblastine (1.2 mg/m2/day for 4 days or 1.5 mg/m2/day for 5 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High-dose tamoxifen (400 mg/m2 loading dose and 300 mg/m2/day for 13 days) with continuous-infusion vinblastine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Continuous-infusion vinblastine alone (1.2 mg/m2/day for 4 days or 1.5 mg/m2/day for 5 days)
Number of subjects: 63
Study: 7962322

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Dietary lipids
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Dietary and crude fiber
Number of subjects: 1241
Study: 3503318

Group type: EXPERIMENTAL
Intervention: Unlocked car door condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Locked car door condition
Number of subjects: 80
Study: 29329061

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 10, 20, 30, 45, or 60 minutes with recovery periods of 5, 15, or 30 minutes
Number of subjects: 352

Group type: COMPARATOR
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 60 minutes with 5 minutes recovery
Number of subjects: 352

Group type: COMPARATOR
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 10 minutes
Number of subjects: 352
Study: 28499391

Group type: EXPERIMENTAL
Intervention: Chondrosphere® (low dose: 3-7 spheroids/cm², medium dose: 10-30 spheroids/cm², high dose: 40-70 spheroids/cm²)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chondrosphere® (all dose levels)
Number of subjects: 75
Study: 25582116

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 139

Group type: COMPARATOR
Intervention: SAD participants
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: All strategies
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Psychophysiological parameters
Number of subjects: 139